Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0AYTGS
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
PF-08046037
|
|||||
| Synonyms |
PF-08046037; SGN-PDL1iT
Click to Show/Hide
|
|||||
| Organization |
Pfizer (Originator) (Top20 MNC)
|
|||||
| Drug Status |
Phase 1 (discontinued)
|
|||||
| Antibody Name |
Anti-PD-L1 antibody
|
Antibody Info | ||||
| Antigen Name |
Programmed cell death ligand 1 (PD-L1); Leukocyte surface antigen CD47 (CD47)
|
Antigen Info | ||||
| Payload Name |
Imidazoquinoline-based TLR7 agonist
|
Payload Info | ||||
| Therapeutic Target |
Toll-like receptor 7 (TLR7)
|
Target Info | ||||
| Linker Name |
Mannosidase-cleavable maleimidopropionyl-mannose linker
|
Linker Info | ||||
| Conjugate Type |
Undisclosed
|
|||||
The indication landscape of This ADC(2027 Update)
The clinical trial pipeline of This ADC(2027 Update)
| Indication | Phase 1 | Phase 1/2 | Phase 2 | Phase 2/3 | Phase 3 | New Drug Application | Approved | ||
|---|---|---|---|---|---|---|---|---|---|
| Head and neck cancer |
1 Trials
|
||||||||
| Lung cancer |
1 Trials
|
||||||||
| Melanoma |
1 Trials
|
||||||||
| Pancreatic cancer |
1 Trials
|